Wedbush raised the firm’s price target on Praxis Precision (PRAX) to $83 from $77 and keeps an Underperform rating on the shares. The firm notes the company completed its pre-NDA meeting with FDA for ulixacaltamide. Most notable, Praxis will submit its ulixacaltamide NDA in early-2026. This is consistent with Wedbush expectations as its areas of concern are all issues that would be handled in review vs. a pre-NDA meeting.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Praxis Precision Medicines: Buy Rating Affirmed on Regulatory Milestones and Promising Pipeline Developments
- Praxis Precision price target raised to $499, named 2026 top pick at BTIG
- Praxis Precision price target raised to $340 from $258 at H.C. Wainwright
- Closing Bell Movers: Rubrik up 14% on earnings beat; Oklo down on $1.5B offering
- Praxis Precision announces results from EMBOLD study cohort